“…Multicolor flow cytometric analysis was performed using the FACSCanto II (BD Biosciences, San Jose, CA, USA) as previously described . The following antibodies were used: fluorescein isothiocyanate (FITC)‐conjugated anti‐CD62L (MEL14), phycoerythrin (PE)‐conjugated anti‐CD127 (A7R34), PE‐conjugated anti‐CD45.1 (A20), PECy7‐conjugated anti‐CD62L (MEL14), PE‐conjugated anti‐CD4 (GK1.5), PE‐conjugated anti‐CD11b (M1/70), PE‐conjugated anti‐B220 (RA3‐6B2), PE‐conjugated anti‐Ter119 (TER‐119), PE‐conjugated anti‐γd TCR (eBioGL3), PECy7‐conjugated anti‐Eomes (Dan11mag), PE‐conjugated GATA3 (TWAJ), PE‐conjugated RORγt (AFKJS‐9), PE‐conjugated FOXP3 (FJK‐16s), PE‐conjugated Ki67 (SolA15), PE‐conjugated CD122 (5H4), allophycocyanin (APC)‐conjugated anti‐CD183 (CXCR3‐173), PE‐conjugated anti‐TNFα (MP6‐XT22), PECy7‐conjugated anti‐IFN‐γ (XMG1.2), PerCpCy5.5‐conjugated anti‐IFN‐γ (XMG1.2), BV421‐conjugated T‐bet (4B10), PE‐conjugated anti‐Ly‐6G (RB6‐8C5), FITC‐conjugated anti‐Vα2 TCR (B20.1) (eBioscience, San Diego, CA, USA), PE‐conjugated anti‐CD19 (6D5), PE‐conjugated anti‐CD5 (53‐7.3), PE‐conjugated anti‐NK1.1 (PK136), PE‐conjugated anti‐CD105 (MJ7/18), PE‐conjugated anti‐CD4 (RM4‐5), FITC‐conjugated anti‐IL‐17 (TC11‐18H10.1), FITC‐conjugated anti‐granzymeB (GB11) (BioLegend, San Diego, CA, USA), PECy7‐conjugated anti‐CD8a (53‐6.7), PE‐conjugated anti‐CD11c (N418) (Tonbo Biosciences, San Diego, CA, USA), FITC‐conjugated anti‐BrdU (3D4), PE‐conjugated anti‐Vβ5.1, and 5.2 TCR (MR‐9‐4) (BD Biosciences).…”